Radiation Oncology Journal

  • 제38권2호
  • /
  • Pages.109-118
  • /
  • 2020
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer

  • Yadav, Budhi Singh (Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education & Research) ;
  • Bansal, Anshuma (Department of Radiation Oncology, Rajindra Hospital) ;
  • Kuttikat, Philip George (Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education & Research) ;
  • Das, Deepak (Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education & Research) ;
  • Gupta, Ankita (Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education & Research) ;
  • Dahiya, Divya (Department of General Surgery, Postgraduate Institute of Medical Education & Research)
  • 투고 : 2020.03.18
  • 심사 : 2020.05.04
  • 발행 : 2020.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Hypofractionated radiotherapy (RT) is becoming a new standard in postoperative treatment of patients with early stage breast cancer after breast conservation surgery. However, data on hypofractionation in patients with advanced stage disease who undergo mastectomy followed by local and regional nodal irradiation (RNI) is lacking. In this retrospective study, we report late-term effects of 3 weeks post-mastectomy hypofractionated local and RNI with two-dimensional (2D) technique in patients with stage II and III breast cancer. Methods: Between January 1990 and December 2007, 1,770 women with breast cancer who were given radical treatment with mastectomy, systemic therapy and RT at least 10 years ago were included. RT dose was 35 Gy/15 fractions/3 weeks to chest wall by two tangential fields and 40 Gy in same fractions to supraclavicular fossa (SCF) and internal mammary nodes (IMNs). SCF and IMNs dose was prescribed at dmax and 3 cm depth, respectively. Chemotherapy and hormonal therapy was given in 64% and 74% patients, respectively. Late-term toxicities were assessed with the Radiation Therapy Oncology Group (RTOG) scores and LENT-SOMA scales (the Late Effects Normal Tissue Task Force-Subjective, Objective, Management, Analytic scales). Results: Mean age was 48 years (range, 19 to 75 years). Median follow-up was 12 years (range, 10 to 27 years). Moderate/marked arm/shoulder pain was reported by 254 (14.3%) patients. Moderate/marked shoulder stiffness was reported by 219 (12.3%) patients. Moderate/marked arm edema was seen in 131 (7.4%) patients. Brachial plexopathy was not seen in any patient. Rib fractures were noted in 6 (0.3%) patients. Late cardiac and lung toxicity was seen in 29 (1.6%) and 23 (1.3%) patients, respectively. Second malignancy developed in 105 (5.9%) patients. Conclusion: RNI with 40 Gy/15 fractions/3 weeks hypofractionation with 2D technique seems safe and comparable to historical data of conventional fractionation (ClinicalTrial.gov Registration No. NCT04175821).

키워드

참고문헌

  1. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoad-juvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804. https://doi.org/10.1200/JCO.2011.38.8595
  2. START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331-41. https://doi.org/10.1016/S1470-2045(08)70077-9
  3. START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098-107. https://doi.org/10.1016/S0140-6736(08)60348-7
  4. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086-94. https://doi.org/10.1016/S1470-2045(13)70386-3
  5. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355:1757-70. https://doi.org/10.1016/S0140-6736(00)02263-7
  6. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019;20:352-60. https://doi.org/10.1016/s1470-2045(18)30813-1
  7. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-20. https://doi.org/10.1056/NEJMoa0906260
  8. Khan AJ, Poppe MM, Goyal S, et al. Hypofractionated postmastectomy radiation therapy is safe and effective: first results from a prospective phase II trial. J Clin Oncol 2017;35:2037-43. https://doi.org/10.1200/JCO.2016.70.7158
  9. Yadav BS, Sharma SC, Ghoshal S, Kapoor RK, Kumar N. Postmastectomy internal mammary node radiation in women with breast cancer: a long-term follow-up study. J Radiother Pract 2015;14:385-93. https://doi.org/10.1017/S1460396915000278
  10. Yadav BS, Sharma SC, Singh R, Singh G. Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther 2007;3:75-80. https://doi.org/10.4103/0973-1482.34683
  11. Yadav BS, Sharma SC, Singh R, Singh G, Kumar V. Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther 2007;3:218-24. https://doi.org/10.4103/0973-1482.38997
  12. Yadav BS, Sharma SC, Patel FD, Bose SM, Ghoshal S, Kapoor RK. Therapeutic benefit of radiotherapy after surgery in patients with T1-T2 breast tumour. J Radiother Pract 2010;9:33-40. https://doi.org/10.1017/S1460396909990124
  13. Yadav BS, Sharma SC, George P, Bansal A. Post-mastectomy radiation beyond chest wall in patients with N1 breast cancer: is there a benefit? J Cancer Res Ther 2014;10:279-83. https://doi.org/10.4103/0973-1482.136560
  14. Van Parijs H, Miedema G, Vinh-Hung V, et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol 2012;7:80. https://doi.org/10.1186/1748-717X-7-80
  15. Pinitpatcharalert A, Chitapanarux I, Euathrongchit J, Tharavichitkul E, Sukthomya V, Lorvidhaya V. A retrospective study comparing hypofractionated radiotherapy and conventional radiotherapy in postmastectomy breast cancer. J Med Assoc Thai 2011;94 Suppl 2:S94-102.
  16. Poortmans P, Kouloulias V, van Tienhoven G, et al. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works. Strahlenther Onkol 2006;182:576-82. https://doi.org/10.1007/s00066-006-1629-2
  17. Koukourakis MI, Panteliadou M, Abatzoglou IM, Sismanidou K, Sivridis E, Giatromanolaki A. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection. Int J Radiat Oncol Biol Phys 2013;85:e7-13. https://doi.org/10.1016/j.ijrobp.2012.08.017
  18. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 2015;114:3-10. https://doi.org/10.1016/j.radonc.2014.11.030
  19. Radiation Therapy Oncology Group. Breast cancer atlas for radiation therapy planning: consensus definitions [Internet]. Philadelphia, PA: Radiation Therapy Oncology Group; 2016 [cited 2020 May 10]. Available from: https://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx.
  20. Donker M, Slaets L, van Tienhoven G, Rutgers EJ. Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial. Ned Tijdschr Geneeskd 2015;159:A9302.
  21. Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys 2012;83:1095-100. https://doi.org/10.1016/j.ijrobp.2011.09.058
  22. Ugur S, Arici C, Yaprak M, et al. Risk factors of breast cancer-related lymphedema. Lymphat Res Biol 2013;11:72-5. https://doi.org/10.1089/lrb.2013.0004
  23. Jung SY, Shin KH, Kim M, et al. Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat 2014;148:91-8. https://doi.org/10.1007/s10549-014-3137-x
  24. Chandra RA, Miller CL, Skolny MN, et al. Radiation therapy risk factors for development of lymphedema in patients treated with regional lymph node irradiation for breast cancer. Int J Radiat Oncol Biol Phys 2015;91:760-4. https://doi.org/10.1016/j.ijrobp.2014.12.029
  25. Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys 2011;79:1-9. https://doi.org/10.1016/j.ijrobp.2010.08.035
  26. Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA. 20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011;29(18_suppl):LBA1003.
  27. Badiyan SN, Shah C, Arthur D, et al. Hypofractionated regional nodal irradiation for breast cancer: examining the data and potential for future studies. Radiother Oncol 2014;110:39-44. https://doi.org/10.1016/j.radonc.2013.12.006
  28. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005;75:9-17. https://doi.org/10.1016/j.radonc.2005.01.005
  29. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467-71. https://doi.org/10.1016/S1470-2045(06)70699-4
  30. Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor RK. Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol 2008;86:171-6. https://doi.org/10.1016/j.radonc.2007.10.002
  31. Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor R, Kumar R. Nonbreast second malignancies after treatment of primary breast cancer. Int J Radiat Oncol Biol Phys 2009;73:1489-92. https://doi.org/10.1016/j.ijrobp.2008.07.004
  32. Yadav BS, Sharma SC, Patel FD, Rai B, Ghoshal S. Gynecological Cancer as a Second Malignancy in Patients With Breast Cancer. Int J Gynecol Cancer 2017;27:1298-304. https://doi.org/10.1097/igc.0000000000000993
  33. International Atomic Energy Agency. Planning national radiotherapy services: a practical tool. Vienna, Austria: International Atomic Energy Agency; 2010.
  34. Hahn C, Kavanagh B, Bhatnagar A, et al. Choosing wisely: the American Society for Radiation Oncology's top 5 list. Pract Radiat Oncol 2014;4:349-55. https://doi.org/10.1016/j.prro.2014.06.003
  35. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018;8:145-52. https://doi.org/10.1016/j.prro.2018.01.012